4BIO Capital — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Cytospire Therapeuticscytospire.comSeries A · May 2026 · $83M
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesPathway BioventuresSound Bioventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.



